Raymond James downgraded Teleflex from Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2025 | $235.00 → $140.00 | Neutral → Underperform | BofA Securities |
| 2/28/2025 | $220.00 → $155.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 2/28/2025 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2025 | $255.00 → $140.00 | Overweight → Neutral | Piper Sandler |
| 2/27/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 7/1/2024 | $205.00 → $245.00 | Neutral → Overweight | Piper Sandler |
| 12/4/2023 | $261.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/21/2023 | Buy → Hold | Needham |
BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously
RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously
Raymond James downgraded Teleflex from Outperform to Mkt Perform
SD - TELEFLEX INC (0000096943) (Filer)
8-K - TELEFLEX INC (0000096943) (Filer)
10-Q - TELEFLEX INC (0000096943) (Filer)
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With
WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.21 in the prior year period 2025 guidance summary Raising GAAP revenue growth guidance range to 1.28% to 2.28% Maintaining adjusted constant currency revenue growth guidan
WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all ot
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights include: The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days.70.5% reduction in the incidence of CLABSI in patien
Timed with National Men's Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and the importance of organ spacing to protect against potential rectal side effects in advance of prostate cancer radiation treatment. WAYNE, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading globa
Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a global leader in medical technologies, today announced the presentation of compelling new clinical data at the 2025 American Urological Association (AUA) Annua